Volume 23, Number 6 (December 2016) The latest issue of Current Oncology is now available online. Please visit the following link to view full text a

Current oncology 560x100 option 1-01

Volume 23, Number 6 (December 2016)

The latest issue of Current Oncology is now available online. Please visit the following link to view full text articles from this issue:


Upcoming in Current Oncology

The future table of contents for Current Oncology, Volume 24, Number 1 (February 2017) is now available. For the most up-to-date listing of scheduled papers, please visit the following link:

Highlights from this issue…

The Two Solitudes of Primary Care and Cancer Specialist Care: A collection of papers from CanIMPACT (Canadian Team to Improve Community-based Cancer Care along the Continuum), that describe and seek to understand the nature of the two solitudes within the Canadian context as well as initiatives that attempt to bridge the two solitudes.

Impact Mediacom Logo

Updates from the American Society of Hematology Meeting: The annual American Society of Hematology (ASH) meeting took place this year in San Diego, California from December 3–6, 2016. At the meeting, results from key studies on the first-line treatment of follicular lymphoma (FL) were presented. Of the studies presented, key oral presentations included: 2 studies analysing data from the GALLIUM study, which compared the efficacy and safety of obinutuzumab plus chemotherapy (G-chemo) versus rituximab plus chemotherapy (R-chemo) followed by G- or R-maintenance in responding FL patients; results from SABRINA, comparing the efficacy and safety of subcutaneous versus intravenous R; results from the SAKK 35/10 study, comparing the safety and efficacy of R plus lenalidomide versus R monotherapy; and results from a cost-effectiveness study of first-line treatment with bendamustine and rituximab from a Canadian perspective. In the upcoming meeting summary, a summary of the above studies is provided along with interviews with Canadian investigators and commentaries on their potential impact for Canadian practice.

publisher 1

As we approach 2017, we would like to take this opportunity to thank our Editors, Authors and Industry Supporters for their valuable contribution and support of the journal. We would also like to thank our Reviewers, who volunteer their time and effort to ensure the high standards of the journal are met. The constructive criticism and insightful comments they provide to Current Oncology authors is integral to enhancing the quality of articles that we publish. The names of those who participated in peer review during 2016 can be viewed by clicking here.

2016 was an exciting year for the journal, as highlighted by:
• An increased Impact Factor of 1.829
• Launch of our new logo and journal cover design
• Publication of the supplemental issues “Use of Cannabinoids in Cancer Care” and “Original Cancer Costing Research Using Canadian Data
• Extended journal reach and reader engagement through Twitter – the journal now has over 400 followers!

We have exciting plans for the journal in 2017 to ensure it continues to strengthen and grow. Here is a preview of what is upcoming in the year ahead:
• Special supplemental issue dedicated to the advances in breast & lung cancers for the community oncologist; edited by Drs. Barb Melosky, Vera Hirsh and Susan Dent
• Coming February 2017 – A collection of papers from CanIMPACT (Canadian Team to Improve Community-based Cancer Care along the Continuum), which describes, seeks to understand, and attempts to bridge the gap between the two solitudes of Primary Care and Cancer Specialist Care
• Reapplication to MEDLINE, the U.S. National Library of Medicine (NLM) premier bibliographic database

Stay tuned for more information in future newsletters!

Best wishes for a happy holiday season,


Multimed Inc.
Publisher of Current Oncology


Fred Saad, MD FRCS
Editor of our Urologic Oncology Section (since 2002)

Fred Saad MD FRCS, is Professor and Chairman of Urology and Director of G-U Oncology at the University of Montreal Hospital Centers (CHUM). He holds the U of M Endowed Chair in Prostate Cancer Research and is Director of the molecular oncology research lab in Prostate Cancer. He is the past Chair of the National Cancer Institute of Canada G-U Group and the Canadian Urologic Oncology Group. Dr Saad has been involved in most of the important clinical trials in advanced prostate cancer over the last 20 years and presently sits on 7 steering committees of international clinical trials. He serves on several international guidelines committees and sits on 7 editorial boards, including Lancet Oncology, JAMA Oncology, Nature Urology, Urology as well as Current Oncology. He has published 350 peer-reviewed articles, as well as over 1000 scientific abstracts, 8 books and over 50 book chapters. Dr Saad’s research interests include molecular prognostic markers, mechanisms of progression and new therapeutics in prostate cancer. He has over 40 clinical and basic research projects ongoing and has received over 30 million dollars in research grants to date.

twitter banner e-newsletter

Patients and their Families Always the Focus for Award-winning Nurse

Angela Leahey of Toronto's Sunnybrook Health Sciences Centre has been named 2016 Boehringer Ingelheim Oncology Nurse of the Year.

Ms. Leahey is the Professional Leader in Oncology Nursing and Manager for Advanced Practice Nurses in Oncology and Palliative Care at the Odette Cancer Centre at Sunnybrook. She is also the Regional Lead for Oncology Nursing in her area.

She was nominated by her peers for her lead in developing the Nurse Triage Role and Teletriage (a live voice nursing phone line) for cancer patients, initiatives geared toward quickly identifying patients in distress and with the greatest need for nursing resources both in clinic and while at home.

The fifth annual Boehringer Ingelheim Oncology Nurse of the Year award was presented at the Canadian Association of Nurses in Oncology (CANO/ACIO) Annual Conference, held this year in October in Calgary. The award recognizes the unique contributions of an oncology nurse who consistently demonstrates the highest level of nursing excellence and leadership.

“We are pleased to recognize Ms. Leahey for the fifth annual Boehringer Ingelheim Nurse of the Year Award, and we acknowledge all the passionate and caring nurses like her who were nominated,” said Richard Mole, President & CEO, Boehringer Ingelheim (Canada) Ltd. “The direct impact they make on the lives of patients and their families is invaluable. It is clear from Ms. Leahey’s work that she is a skilled innovator and leader, and it is nurses like her who help move this specialty forward.”


Have you had the chance to view these Current Oncology “Most-Read” articles?

Most Read Articles in PubMed Central (November 2016)

Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls
Pereira J.
Curr Oncol. 2011 Apr;18(2):e38-45

A legal right to die: responding to slippery slope and abuse arguments
Benatar D.
Curr Oncol. 2011 Oct;18(5):206-7

Do statins prevent or promote cancer?
Goldstein, M.
Curr Oncol. 2008 Apr; 15(2): 76–77

Most Read Recently* Published Articles at www.current-oncology.com

Use of cannabinoids in cancer care: palliative care
Aggarwal SK.
Curr Oncol. 2016 Mar;23(Suppl 2):S33-6. doi: 10.3747/co.23.2962. Epub 2016 Mar 16.

Anticancer mechanisms of cannabinoids
Velasco G, Sánchez C, Guzmán M
Curr Oncol. 2016 Mar;23(Suppl 2):S23-32. doi: 10.3747/co.23.3080. Epub 2016 Mar 16.

Integrating cannabis into clinical cancer care
D.I. Abrams
Curr Oncol. 2016 Mar;23(Suppl 2):S8-14. doi: 10.3747/co.23.3099. Epub 2016 Mar 16.

*Published within past 12 months


Innovative Approaches to Optimal Cancer Care in Canada

April 7-8, 2017
Toronto, ON

Innovative Approaches to Optimal Cancer Care in Canada is a one-of-a-kind opportunity to connect with cancer colleagues from across Canada and learn about innovations in cancer care.

The conference will feature renowned international and Canadian speakers who’s insights span the cancer care continuum – screening, diagnosis and treatment, palliative and end-of-life care, and survivorship. Join us as we’ll delve into key themes:
• Quality of care for all
• Diagnostic processes: A clear pathway or a revolving door?
• Overcoming inertia in the cancer system: why don't we do what we know works?

Registration and a Call for Abstracts for oral and poster presentation is now open. Learn more.

Attend the CAPhO Conference 2017 in Banff, Alberta and “Do Something Astonishing”

CAPhO Conference 2017 (CAPhO 2017), presented by the Canadian Association of Pharmacy in Oncology (CAPhO), will take place from April 20 to 23, 2017 at The Fairmont Banff Springs Hotel in Banff, Alberta.

With the theme Do Something Astonishing, the CAPhO 2017 program promises to be engaging, current and educational, giving us all the means to practice with purpose.

Visit the CAPhO Conference website for information on how to register, submit a poster abstract and sign up for our E-Newsletter to receive automatic updates about the Conference.


Contact Us